News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Forest Laboratories, Inc. (FRX) Seen Needing M&A Deals Amid Patent Losses



7/6/2012 7:04:55 AM

Forest Laboratories Inc. (FRX) needs acquisitions to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire. About three-quarters of the company’s more than $4.5 billion of sales last year were generated by the antidepressant Lexapro, which lost exclusivity in March, and Namenda, an Alzheimer’s treatment facing the end of its patent protection in 2015. Net income at New York-based Forest, where costs have risen faster than sales over the last five years, is projected to tumble the most in at least 16 years, according to analysts’ estimates compiled by Bloomberg.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES